The TAILORx trial: Individualized options for treatment

Joseph A. Sparano

Research output: Contribution to journalShort surveypeer-review

11 Scopus citations


Because predicting treatment benefit is imprecise, when faced with making a decision on whether to accept adjuvant chemotherapy, many patients with ER-positive breast cancer and their clinicians err on the side of overtreatment. The TAILORx trial will attempt to reduce overtreatment by integrating a molecular diagnostic test into clinical decision making; identifying the utility of chemotherapy in patients where the molecular test gives a result of uncertain clinical significance; and serving as a resource to evaluate new molecular tests as they develop. This article describes the trial and how clinicians can enroll their patients.

Original languageEnglish (US)
Pages (from-to)494-496
Number of pages3
JournalCommunity Oncology
Issue number8
StatePublished - Aug 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The TAILORx trial: Individualized options for treatment'. Together they form a unique fingerprint.

Cite this